≡

Recombinant Retinoschisin (RS)

RS1; XLRS1; Retinoschisis X-Linked,Juvenile 1; X-linked juvenile retinoschisis protein

  • Product No.RPJ847Hu01
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted
  • Predicted Molecular Mass53.0kDa
  • Accurate Molecular Mass53kDa(Analysis of differences refer to the manual)
  • Residues & TagsSer24~Ala224 with N-terminal His and GST Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder
  • Purity> 80%
  • Isoelectric Point5.5
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 160  US$ 400  US$ 800  US$ 2400  US$ 6000 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Hum Gene Ther Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. PubMed: 22295905
IEEE Transactions on Magnetics Influence of Iron Oxide Nanoparticles on Innate and Genetically Modified Secretion Profiles of Mesenchymal Stem Cells Scholarsportal: Source
International Journal of Pharmaceutics A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases Pubmed:24576595
22 Structural recovery of the retina in a retinoschisin-deficient mouse after gene replacement therapy by solid lipid nanoparticles Pubmed:26986855
UBC Library Cell based therapeutics for retinal degenerations cIRcle:1.0303136
Molecular Vision An ex vivo gene therapy approach in X-linked retinoschisis pubmed:27390514
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPJ847Hu01 Recombinant Retinoschisin (RS) Positive Control; Immunogen; SDS-PAGE; WB.
PAJ847Hu01 Polyclonal Antibody to Retinoschisin (RS) WB
MAJ847Hu21 Monoclonal Antibody to Retinoschisin (RS) WB; IHC; ICC; IP.
SEJ847Hu ELISA Kit for Retinoschisin (RS) Enzyme-linked immunosorbent assay for Antigen Detection.
SCJ847Hu CLIA Kit for Retinoschisin (RS) Chemiluminescent immunoassay for Antigen Detection.
LMJ847Hu Multiplex Assay Kit for Retinoschisin (RS) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.